Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29733654 | 1.00 | KDR (0.53) | KDRCHEK1RAB9ANPC1KDM4E | |
| SCHEMBL29419326 | 1.00 | KDR (0.53) | KDRCHEK1RAB9ANPC1KDM4E | |
| Hydrochloric Acid SCHEMBL31035997 | 0.98 | KDR (0.51) | KDRCHEK1RAB9ANPC1KDM4E | |
| Hydrochloric Acid SCHEMBL3675763 | 0.98 | KDR (0.51) | KDRCHEK1RAB9ANPC1KDM4E | |
| Hydrochloric Acid SCHEMBL5683292 | 0.98 | KDR (0.51) | KDRCHEK1RAB9ANPC1KDM4E | |
| SCHEMBL8965829 | 0.85 | RAB9A (0.58) | KDRCHEK1RAB9ANPC1KDM4E | |
| SCHEMBL221259 | 0.84 | KDR (0.58) | KDRCHEK1RAB9ANPC1KDM4E | |
| SCHEMBL29361867 | 0.84 | KDR (0.58) | KDRCHEK1RAB9ANPC1KDM4E | |
| SCHEMBL9469591 | 0.83 | RAB9A (0.58) | KDRCHEK1RAB9ANPC1KDM4E | |
| SCHEMBL9469103 | 0.80 | KDR (0.46) | KDRCHEK1RAB9ANPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116482379-A | Method, application, device, computer device and storage medium for diagnosing sperm conventional in vitro fertilization results | 中信湘雅生殖与遗传专科医院有限公司 | 2023-07-25 | — | — | CN | claimed |
| EP-1549949-B1 | METHOD FOR DETECTING AND LIMITING BREAST CARCINOMA RISK BY A MICRONUCLEUS TEST OF BINUCLEAR CELLS | VOGEL WALTER (DE) | 2010-02-17 | — | — | EP | claimed |
| EP-0599337-B1 | Method for detection of nucleic acid and probe therefor | CANON KK (JP) | 2006-03-08 | — | — | EP | claimed |
| EP-1549949-A2 | METHOD FOR DETECTING AND LIMITING BREAST CARCINOMA RISK BY A MICRONUCLEUS TEST OF BINUCLEAR CELLS | Vogel, Walter (DE) | 2005-07-06 | — | — | EP | claimed |
| WO-2004034055-A2 | METHOD FOR DETECTING AND LIMITING BREAST CARCINOMA RISK BY A MICRONUCLEUS TEST OF BINUCLEAR CELLS | VOGEL WALTHER (DE) | 2004-04-22 | — | — | WO | claimed |
| WO-2002014859-A1 | MICRONUCLEUS ASSAY | DIATECH PTY LTD (AU) | 2002-02-21 | — | — | WO | claimed |
| US-20260115323-A1 | METHOD FOR TREATING X-LINKED RETINOSCHISIS | TAIPEI VETERANS GENERAL HOSPITAL (TW) | 2026-04-30 | — | — | US | disclosed |
| US-12533350-B2 | Use of melanocortin-1 receptor agonist | Tanabe Pharma Corporation (JP) | 2026-01-27 | — | — | US | disclosed |
| US-20250381174-A1 | NOVEL USE OF MELANOCORTIN-1 RECEPTOR AGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-12-18 | — | — | US | disclosed |
| EP-4603586-A1 | INHIBITORY OLIGONUCLEOTIDES AGAINST ADAMTS7 | Universität zu Lübeck (DE) | 2025-08-20 | — | — | EP | disclosed |
| US-20250134879-A1 | NOVEL USE OF MELANOCORTIN-1 RECEPTOR AGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-05-01 | — | — | US | disclosed |
| US-12214026-B2 | Vaccine for falciparum malaria | RHODE ISLAND HOSPITAL (US) | 2025-02-04 | — | — | US | disclosed |
| EP-4473967-A1 | NOVEL USE OF MELANOCORTIN-1 RECEPTOR AGONIST | Mitsubishi Tanabe Pharma Corporation (JP) | 2024-12-11 | — | — | EP | disclosed |
| EP-1103609-A1 | DIFFERENTIATION REGULATORY FACTOR EXPRESSED SPECIFICALLY IN TESTIS | Chugai Research Institute for Molecular Medicine Inc. (JP) | 2001-05-30 | — | — | EP | disclosed |
| WO-2001029062-A2 | METHOD FOR MODULATION OF CELL PHENOTYPE | UNIVERSITY TECHNOLOGY CORPORATION (US) | 2001-04-26 | — | — | WO | disclosed |
| EP-1007072-A1 | GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTORS | CEPHALON, INC. (US) | 2000-06-14 | — | — | EP | disclosed |
| EP-1004665-A1 | SCAVENGER RECEPTOR-LIKE PROTEINS | JAPAN TOBACCO INC. (JP) | 2000-05-31 | — | — | EP | disclosed |
| WO-1998052591-A1 | GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTORS | CEPHALON INC. (US) | 1998-11-26 | — | — | WO | disclosed |
| US-5620689-A | ADMINISTERING A SUSPENSION OF LIPOSOMES HAVING A SURFACE COATING OF POLYETHYLENE GLYCOL CHAINS | SEQUUS PHARMACEUUTICALS, INC. (US) | 1997-04-15 | — | — | US | disclosed |
| EP-0519866-A1 | Novel anti-HIV antibodies | CIBA-GEIGY AG (CH) | 1992-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533350-B2 | Use of melanocortin-1 receptor agonist | MC1R, CMKLR1, MC3R | KDR 475/4885CHEK1 4238/4885RAB9A 2725/4885 |
| US-20260115323-A1 | METHOD FOR TREATING X-LINKED RETINOSCHISIS | XBP1, EIF2AK4, RPS6KB2 | KDR 2594/4885CHEK1 3047/4885RAB9A 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.